Targeting the TCR: T-cell receptor and peptide-specific tolerance-based strategies for restoring self-tolerance in CNS autoimmune disease

International Reviews of Immunology

Volumn 24, Issue 5-6, 2005, Pages 361-392

  Kohm, Adam P ^a   Turley, Danielle M ^a   Miller, Stephen D ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Autoimmunity; Costimulation; Non mitogenic anti CD3; Regulatory T cells; Tolerance

Indexed keywords

CD4 ANTIGEN; CYCLOSPORIN; GAMMA INTERFERON; GLATIRAMER; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; MONOCLONAL ANTIBODY CD3; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; OKT 3; PEPTIDE DERIVATIVE; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ENCEPHALOMYELITIS; ANTIGEN SPECIFICITY; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CLONAL ANERGY; COMPARATIVE STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; EFFECTOR CELL; FOLLOW UP; GRAFT REJECTION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOREACTIVITY; IMMUNOREGULATION; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; LONG TERM CARE; LYMPHOCYTE FUNCTION; MITOGENESIS; MOLECULAR RECOGNITION; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; RECEPTOR DOWN REGULATION; REGULATORY MECHANISM; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES; T CELL DEPLETION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; CLINICAL TRIALS; CYTOKINES; HUMANS; IMMUNOSUPPRESSION; IMMUNOTHERAPY; MODELS, IMMUNOLOGICAL; MULTIPLE SCLEROSIS; PEPTIDES; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, INTERLEUKIN-2; SELF TOLERANCE; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 28744457279     PISSN: 08830185     EISSN: None     Source Type: Journal    
DOI: 10.1080/08830180500371207     Document Type: Review

References (122)

1. H. Wekerle, Immunopathogenesis of multiple sclerosis, Acta Neurol., 13: 197-204, 1991.
2. K. Ota, M. Matsui, E.L. Milford, G.A. Mackin, H.L. Weiner, and D.A. Hafler, T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis, Nature, 346: 183-187, 1990.
3. C.C. Bernard and N.K. de Rosbo, Immunopathological recognition of autoantigens in multiple sclerosis, Acta Neurologica, 13: 171-178, 1991.
4. N.K. de Rosbo, M. Hoffman, I. Mendel, I. Yust, J. Kaye, R. Bakimer, S. Flechter, O. Abramsky, R. Milo, A. Karni, et al., Predominance of the autoimmune response to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis: Reactivity to the extracellular domain of MOG is directed against three main regions, Eur. J. Immunol., 27: 3059-3069, 1997.
5. G.C. Ebers, A.D. Sadovnick, and N.J. Risch, A genetic basis for familial aggregation in multiple sclerosis, Nature, 377: 150-151, 1995.
6. J.F. Kurtzke, Epidemiologic evidence for multiple sclerosis as an infection, Clin. Microbiol. Rev., 6: 382-427, 1993.
7. B.H. Waksman, Multiple sclerosis: More genes versus environment, Nature, 377: 105-106, 1995.
8. J.K. Olson, J.L. Croxford, and S.D. Miller, Virus-induced autoimmunity: Potential role of viruses in initiation, perpetuation, and progression of T cell-mediated autoimmune diseases, Viral Immunol., 14: 227-250, 2001.
9. R.S. Fujinami and M.B. Oldstone, Amino acid homology between the encephalitogenic site of myelin basic protein and virus: Mechanism for autoimmunity, Science, 230: 1043-1045, 1985.
10. K.W. Wucherpfennig and J.L. Strominger, Molecular mimicry in T cell-mediated autoimmunity: Viral peptides activate human T cell clones specific for myelin basic protein, Cell, 80: 695-705, 1995.
11. S.D. Miller and W.J. Karpus, The immunopathogenesis and regulation of T-cell mediated demyelinating diseases, Immunol. Today, 15: 356-361, 1994.
12. B.L. McRae, C.L. Vanderlugt, M.C. Dal Canto, and S.D. Miller, Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis, J. Exp. Med., 182: 75-85, 1995.
13. U. Christen and M.G. von Herrath, Initiation of autoimmunity, Curr. Opin. Immunol., 16: 759-767, 2004.
14. X. Zhang, R. Hupperts, and M. De Baets, Monoclonal antibody therapy in experimental allergic encephalomyelitis and multiple sclerosis, Immunol. Res., 28: 61-78, 2003.
15. N.J. Karandikar, C.L. Vanderlugt, J.A. Bluestone, and S.D. Miller, Targeting the B7/CD28:CTLA-4 costimulatory system in CNS autoimmune disease, J. Neuroimmunol., 89: 10-18, 1998.
16. M.E. Call and K.W. Wucherpfennig, The T cell receptor: Critical role of the membrane environment in receptor assembly and function, Annu. Rev. Immunol., 23: 101-125, 2005.
17. O. Leo, M. Foo, D.H. Sachs, L.E. Samelson, and J.A. Bluestone, Identification of a monoclonal antibody specific for a murine T3 polypeptide, Proc. Natl. Acad. Sci. U. S. A., 84: 1374-1378, 1987.
18. J.P. Van Wauwe, J.R. De Mey, and J.G. Goossens, OKT3: A monoclonal anti-human T lymphocyte antibody with potent mitogenic properties, J. Immunol., 124: 2708-2713, 1980.
19. L. Chatenoud, J. Primo, and J.F. Bach, CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice, J. Immunol., 158: 2947-2954, 1997.
20. M. Belghith, J.A. Bluestone, S. Barriot, J. Megret, J.F. Bach, and L. Chatenoud, TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes, Nat. Med., 9: 1202-1208, 2003.
21. L. Chatenoud, CD3-specific antibody-induced active tolerance: From bench to bed-side, Nat. Rev. Immunol., 3: 123-132, 2003.
22. E.L. Masteller and J.A. Bluestone, Immunotherapy of insulin-dependent diabetes mellitus, Curr. Opin. Immunol., 14: 652-659, 2002.
23. K.C. Herold, W. Hagopian, J.A. Auger, E. Poumian-Ruiz, L. Taylor, D. Donaldson, S.E. Gitelman, D.M. Harlan, D. Xu, R.A. Zivin, et al., Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus, N. Engl. J. Med., 346: 1692-1698, 2002.
24. T.O. Utset, J.A. Auger, D. Peace, R.A. Zivin, D. Xu, L. Jolliffe, M.L. Alegre, J.A. Bluestone, and M.R. Clark, Modified anti-CD3 therapy in psoriatic arthritis: A phase I/II clinical trial, J. Rheumatol., 29: 1907-1913, 2002.
25. R. Hirsch, M. Eckhaus, H. Auchincloss, D.H. Sachs, and J.A. Bluestone, Effects of in vivo administration of anti-T3 monoclonal antibody on T cell function in mice. I. Immunosuppression of transplantation responses, J. Immunol., 140: 3766-3772, 1988.
26. B.G. Weinshenker, B. Bass, S. Karlik, G.C. Ebers, and G.P. Rice, An open trial of OKT3 in patients with multiple sclerosis, Neurology, 41: 1047-1052, 1991.
27. C. Ferran, K. Sheehan, M. Dy, R. Schreiber, S. Merite, P. Landais, L.H. Noel, G. Grau, J. Bluestone, and J.F. Bach, Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: Further evidence for transient in vivo T cell activation, Eur. J. Immunol., 20: 509-515, 1990.
28. D. Abramowicz, L. Schandene, M. Goldman, A. Crusiaux, P. Vereerstraeten, L. De Pauw, J. Wybran, P. Kinnaert, E. Dupont, and C. Toussaint, Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients, Transplantation, 47: 606-608, 1989.
29. R.S. Gaston, M.H. Deierhoi, T. Patterson, E. Prasthofer, B.A. Julian, W.H. Barber, D.A. Laskow, A.G. Diethelm, and J.J. Curtis, OKT3 first-dose reaction: Association with T cell subsets and cytokine release, Kidney Int., 39: 141-148, 1991.
30. R. Hirsch, R.E. Gress, D.H. Pluznik, M. Eckhaus, and J.A. Bluestone, Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells, J. Immunol., 142: 737-743, 1989.
31. M. Alegre, P. Vandenabeele, V. Flamand, M. Moser, O. Leo, D. Abramowicz, J. Urbain, W. Fiers, and M. Goldman, Hypothermia and hypoglycemic induced by anti-CD3 monoclonal antibody in mice: Role of tumor necrosis factor, Eur. J. Immunol., 20: 707-710, 1990.
32. B. Charpentier, C. Hiesse, O. Lantz, C. Ferran, S. Stephens, D. O'Shaugnessy, M. Bodmer, G. Benoit, J.F. Bach, and L. Chatenoud, Evidence that antihuman tumor necrosis factor monoclonal antibody prevents OKT3-induced acute syndrome, Transplantation, 54: 997-1002, 1992.
33. R. Hirsch, L. Chatenoud, R.E. Gress, D.H. Sachs, J.F. Bach, and J.A. Bluestone, Suppression of the humoral response to anti-CD3 monoclonal antibody, Transplantation, 47: 853-857, 1989.
34. E.L. Masteller and J.A. Bluestone, Immunotherapy of insulin-dependent diabetes mellitus, Curr. Opin. Immunol., 14: 652-659, 2002.
35. A.R. Hayward and M. Shriber, Reduced incidence of insulitis in NOD mice following anti-CD3 injection: Requirement for neonatal injection, J. Autoimmun., 5: 59-67, 1992.
36. K.C. Herold, J.A. Bluestone, A.G. Montag, A. Parihar, A. Wiegner, R.E. Gress, and R. Hirsch, Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody, Diabetes, 41: 385-391, 1992.
37. D.A. Vallera, S.F. Carroll, S. Brief, and B.R. Blazar, Anti-CD3 immunotoxin prevents low-dose STZ/interferon-induced autoimmune diabetes in mouse, Diabetes, 41: 457-464, 1992.
38. D. Pipeleers, B. Keymeulen, L. Chatenoud, C. Hendrieckx, Z. Ling, C. Mathieu, B. Roep, and D. Ysebaert, A view on beta cell transplantation in diabetes, Ann. N. Y. Acad. Sci., 958: 69-76, 2002.
39. A.C. Vossen, G.J. Tibbe, M.J. Kroos, J.G. van de Winkel, R. Benner, and H.F. Savelkoul, Fc receptor binding of anti-CD3 monoclonal antibodies is not essential for immunosuppression, but triggers cytokine-related side effects, Eur. J. Immunol., 25: 1492-1496, 1995.
40. S. Bolt, E. Routledge, I. Lloyd, L. Chatenoud, H. Pope, S.D. Gorman, M. Clark, and H. Waldmann, The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties, Eur. J. Immunol., 23: 403-411, 1993.
41. 3 domain of IgG as binding site to Fc receptor on mouse lymphocytes, Nature, 253: 656, 1975.
42. J.A. Smith, Q. Tang, and J.A. Bluestone, Partial TCR signals delivered by FcR-nonbinding anti-CD3 monoclonal antibodies differentially regulate individual Th subsets, J. Immunol., 160: 4841-4849, 1998.
43. M.L. Alegre, J.Y. Tso, H.A. Sattar, J. Smith, F. Desalle, M. Cole, and J.A. Bluestone, An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity, J. Immunol., 155: 1544-1555, 1995.
44. + T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis, J. Immunol., 174: 4525-4534, 2005.
45. M.L. Alegre, L.J. Peterson, D. Xu, H.A. Sattar, D.R. Jeyarajah, K. Kowalkowski, J.R. Thistlethwaite, R.A. Zivin, L. Jolliffe, and J.A. Bluestone, A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo, Transplantation, 57: 1537-1543, 1994.
46. E.S. Woodle, D. Xu, R.A. Zivin, J. Auger, J. Charette, R. O'Laughlin, D. Peace, L.K. Jollife, T. Haverty, J.A. Bluestone, et al., Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection, Transplantation, 68: 608-616, 1999.
47. B. Keymeulen, E. Vandemeulebroucke, A.G. Ziegler, C. Mathieu, L. Kaufman, G. Hale, F. Gorus, M. Goldman, M. Walter, S. Candon, et al., Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes, N. Engl. J. Med., 352: 2598-2608, 2005.
48. V.K. Kuchroo, C.A. Martin, J.M. Greer, S.T. Ju, R.A. Sobel, and M.E. Dorf, Cytokines and adhesion molecules contribute to the ability of myelin proteolipid protein-specific T cell clones to mediate experimental autoimmune encephalomyelitis, J. Immunol., 151: 4371-4382, 1993.
49. S.J. Khoury, W.W. Hancock, and H.L. Weiner, Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain, J. Exp. Med., 176: 1355-1364, 1992.
50. J.E. Merrill, D.H. Kono, J. Clayton, D.G. Ando, D.R. Hinton, and F.M. Hofman, Inflammatory leukocytes and cytokines in the peptide-induced disease of experimental allergic encephalomyelitis in SJL and B10.PL mice, Proc. Natl. Acad. Sci. U. S. A., 89: 574-578, 1992.
51. J.L. Baron, J.A. Madri, N.H. Ruddle, G. Hashim, and C.A. Janeway, Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma, J. Exp. Med., 177: 57-68, 1993.
52. W.S. Begolka, C.L. Vanderlugt, S.M. Rahbe, and S.D. Miller, Differential expression of inflammatory cytokines parallels progression of central nervous system pathology in two clinically distinct models of multiple sclerosis, J. Immunol., 161: 4437-4446, 1998.
53. M.K. Racke, A. Bonomo, D.E. Scott, B. Cannella, A. Levine, C.S. Raine, E.M. Shevach, and M. Rocken, Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease, J. Exp. Med., 180: 1961-1966, 1994.
54. V.K. Kuchroo, M.P. Das, J.A. Brown, A.M. Ranger, S.S. Zamvil, R.A. Sobel, H.L. Weiner, N. Nabavi, and L.H. Glimcher, B7-1 and B7-2 costimulatory molecules differentially activate the Th1/Th2 developmental pathways: Application to autoimmune disease therapy, Cell, 80: 707-718, 1995.
55. K.C. Herold, J.B. Burton, F. Francois, E. Poumian-Ruiz, M. Glandt, and J.A. Bluestone, Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala), J. Clin. Invest., 111: 409-418, 2003.
56. S.L. Constant and K. Bottomly, Induction of Th1 and Th2 CD4 + T cell responses: The alternative approaches, Annu. Rev. Immunol., 15: 297-322, 1997.
57. K.M. Plain, J. Chen, S. Merten, X.Y. He, and B.M. Hall, Induction of specific tolerance to allografts in rats by therapy with non-mitogenic, non-depleting anti-CD3 monoclonal antibody: Association with TH2 cytokines not anergy, Transplantation, 67: 605-613, 1999.
58. G.T. Tran, N. Carter, X.Y. He, T.S. Spicer, K.M. Plain, M. Nicolls, B.M. Hall, and S.J. Hodgkinson, Reversal of experimental allergic encephalomyelitis with non-mitogenic, non-depleting anti-CD3 mAb therapy with a preferential effect on T(h)1 cells that is augmented by IL-4, Int. Immunol., 13: 1109-1120, 2001.
59. R.M. Stack, D.J. Lenschow, G.S. Gray, J.A. Bluestone, and F.W. Fitch, IL-4 treatment of small splenic B cells induces costimulatory molecules B7-1 and B7-2, J. Immunol., 152: 5723-5733, 1994.
60. J.A. Smith, J.Y. Tso, M.R. Clark, M.S. Cole, and J.A. Bluestone, Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy, J. Exp. Med., 185: 1413-1422, 1997.
61. Q. Tang, J.A. Smith, G.L. Szot, P. Zhou, M.L. Alegre, K.J. Henriksen, C.B. Thompson, and J.A. Bluestone, CD28/B7 regulation of anti-CD3-mediated immunosuppression in vivo, J. Immunol., 170: 1510-1516, 2003.
62. E.M. Shevach, CD4+CD25+ suppressor T cells: More questions than answers, Nat. Rev. Immunol., 2: 389-400, 2002.
63. E. Suri-Payer, A.Z. Amar, A.M. Thornton, and E.M. Shevach, CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells, J. Immunol., 160: 1212-1218, 1998.
64. S. Sakaguchi, N. Sakaguchi, M. Asano, M. Itoh, and M. Toda, Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases, J. Immunol., 155: 1151-1164, 1995.
65. B. Salomon, D.J. Lenschow, L. Rhee, N. Ashourian, B. Singh, A. Sharpe, and J.A. Bluestone, B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes, Immunity, 12: 431-440, 2000.
66. A.P. Kohm, P.A. Carpentier, H.A. Anger, and S.D. Miller, Cutting Edge: CD4(+)CD25(+) regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis, J. Immunol., 169: 4712-4716, 2002.
67. S. Hori, M. Haury, A. Coutinho, and J. Demengeot, Specificity requirements for selection and effector functions of CD25+4+ regulatory T cells in anti-myelin basic protein T cell receptor transgenic mice, Proc. Natl. Acad. Sci. U. S. A., 99: 8213-8218, 2002.
68. G.C. Furtado, D. Olivares-Villagomez, M.A. Curotto de Lafaille, A.K. Wensky, J.A. Latkowski, and J. J. Lafaille, Regulatory T cells in spontaneous autoimmune encephalomyelitis, Immunol. Rev., 182: 122-134, 2001.
69. L. Chatenoud, B. Salomon, and J.A. Bluestone, Suppressor T cells - they're back and critical for regulation of autoimmunity!, Immunol. Rev., 182: 149-163, 2001.
70. S.M. O'Herrin, J.E. Slansky, Q. Tang, M.A. Markiewicz, T.F. Gajewski, D.M. Pardoll, J.P. Schneck, and J.A. Bluestone, Antigen-specific blockade of T cells in vivo using dimeric MHC peptide, J. Immunol., 167: 2555-2560, 2001.
71. S.M. Anderton and D.C. Wraith, Selection and fine-tuning of the autoimmune T-cell repertoire, Nat. Rev. Immunol., 2: 487-498, 2002.
72. L.B. Nicholson, A. Murtaza, B.P. Hafler, A. Sette, and V.K. Kuchroo, A T cell receptor antagonist peptide induces T cells that mediate bystander suppression and prevent autoimmune encephalomyelitis induced with multiple myelin antigens, Proc. Natl. Acad. Sci. U. S. A., 94: 9279-9284, 1997.
73. D.A. Young, L.D. Lowe, S.S. Booth, M.J. Whitters, L. Nicholson, V.K. Kuchroo, and M. Collins, IL-4, IL-10, IL-13, and TGF-beta from an altered peptide ligand-specific Th2 cell clone down-regulate adoptive transfer of experimental autoimmune encephalomyelitis, J. Immunol., 164: 3563-3572, 2000.
74. M.F. Samson and D.E. Smilek, Reversal of acute experimental autoimmune encephalomyelitis and prevention of relapses by treatment with a myelin basic protein peptide analogue modified to form long-lived peptide-MHC complexes, J. Immunol., 155: 2737-2746, 1995.
75. D.C. Wraith, D.E. Smilek, D.J. Mitchell, L. Steinman, and H.O. McDevitt, Antigen recognition in autoimmune encephalomyelitis and the potential for peptide-mediated immunotherapy, Cell, 59: 247-255, 1989.
76. L.B. Nicholson and V.K. Kuchroo, T cell recognition of self and altered self antigens, Crit. Rev. Immunol., 17: 449-462, 1997.
77. L.B. Nicholson, J.M. Greer, R.A. Sobel, M.B. Lees, and V.K. Kuchroo, An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis, Immunity, 3: 397-405, 1995.
78. Z. Illes, J.N. Stern, J. Reddy, H. Waldner, M.P. Mycko, C.F. Brosnan, S. Ellmerich, D.M. Altmann, L. Santambrogio, J.L. Strominger, et al., Modified amino acid copolymers suppress myelin basic protein 85-99-induced encephalomyelitis in humanized mice through different effects on T cells, Proc. Natl. Acad. Sci. U. S. A., 101: 11749-11754, 2004.
79. J.N. Stern, Z. Illes, J. Reddy, D.B. Keskin, M. Fridkis-Hareli, V.K. Kuchroo, and J.L. Strominger, Peptide 15-mers of defined sequence that substitute for random amino acid copolymers in amelioration of experimental autoimmune encephalomyelitis, Proc. Natl. Acad. Sci. U. S. A., 102: 1620-1625, 2005.
80. L. Kappos, G. Comi, H. Panitch, J. Oger, J. Antel, P. Conlon, and L. Steinman, Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The altered peptide ligand in relapsing MS study group, Nat. Med., 6: 1176-1182, 2000.
81. B. Bielekova, B. Goodwin, N. Richert, I. Cortese, T. Kondo, G. Afshar, B. Gran, J. Eaton, J. Antel, J.A. Frank, et al., Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand, Nat. Med., 6: 1167-1175, 2000.
82. M.B. Bornstein, A. Miller, S. Slagle, M. Weitzman, H. Crystal, E. Drexler, M. Keilson, A. Merriam, S. Wassertheilsmoller, V. Spada, et al., A pilot trial of Cop-1 in exacerbating remitting multiple-sclerosis, N. Eng. J. Med., 317: 408-414, 1987.
83. R. Aharoni, D. Teitelbaum, R. Arnon, and M. Sela, Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking, Proc. Natl. Acad. Sci. U. S. A., 96: 634-639, 1999.
84. P.W. Duda, M.C. Schmied, S.L. Cook, J.I. Krieger, and D.A. Hafler, Glatiramer acetate (Copaxone (R)) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis, J. Clin. Invest., 105: 967-976, 2000.
85. A.D. Korczyn and P. Nisipeanu, Safety profile of copolymer 1: Analysis of cumulative experience in the United States and Israel, J. Neurol., 243: S23-S26, 1996.
86. L. Mayer and L. Shao, Therapeutic potential of oral tolerance, Nat. Rev. Immunol., 4: 407-419, 2004.
87. A.M. Mowat, S. Strobel, H.E. Drummond, and A. Ferguson, Immunological responses to fed protein antigens in mice. I. Reversal of oral tolerance to ovalbumin by cyclophosphamide, Immunology, 45: 105-113, 1982.
88. A.M. Faria and H.L. Weiner, Oral tolerance: Mechanisms and therapeutic applications, Adv. Immunol., 73: 153-264, 1999.
89. A. Friedman and H.L. Weiner, Induction of anergy or active suppression following oral tolerance is determined by antigen dosage, Proc. Natl. Acad. Sci. U. S. A., 91: 6688-6692, 1994.
90. C.C. Whitacre, I.E. Gienapp, C.G. Orosz, and D.M. Bitar, Oral tolerance in experimental autoimmune encephalomyelitis: III. Evidence for clonal anergy, J. Immunol., 147: 2155-2163, 1991.
91. Y. Chen, V.K. Kuchroo, J. Inobe, D.A. Hafler, and H.L. Weiner, Regulatory T cell clones induced by oral tolerance: Suppression of autoimmune encephalomyelitis, Science, 265: 1237-1240, 1994.
92. A.M. Mowat, L.A. Parker, H. Beacock-Sharp, O.R. Millington, and F. Chirdo, Oral tolerance: Overview and historical perspectives, Ann. N. Y. Acad. Sci., 1029: 1-8, 2004.
93. H.L. Weiner, Current issues in the treatment of human diseases by mucosal tolerance, Ann. N. Y. Acad. Sci., 1029: 211-224, 2004.
94. W.J. Karpus, K.J. Kennedy, W.S. Smith, and S.D. Miller, Inhibition of relapsing experimental autoimmune encephalomyelitis in SJL mice by feeding the immunodominant PLP139-151 molecule, J. Neurosci. Res., 45: 410-423, 1996.
95. X.F. Bai, F.D. Shi, B.G. Xiao, H.L. Li, P.H. van der Meide, and H. Link, Nasal administration of myelin basic protein prevents relapsing experimental autoimmune encephalomyelitis in DA rats by activating regulatory cells expressing IL-4 and TGF-beta mRNA, J. Neuroimmunol., 80: 65-75, 1997.
96. A.L. Meyer, J.M. Benson, I.E. Gienapp, K.L. Cox, and C.C. Whitacre, Suppression of murine chronic relapsing experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein, J. Immunol., 157: 4230-4238, 1996.
97. J.M. Benson, S.S. Stuckman, K.L. Cox, R.M. Wardrop, I.E. Gienapp, A.H. Cross, J.L. Trotter, and C.C. Whitacre, Oral administration of myelin basic protein is superior to myelin in suppressing established relapsing experimental autoimmune encephalomyelitis, J. Immunol., 162: 6247-6254, 1999.
98. X.F. Bai, H.L. Li, F.D. Shi, J.Q. Liu, B.G. Xiao, P.H. van der Meide, and H. Link, Complexities of applying nasal tolerance induction as a therapy for ongoing relapsing experimental autoimmune encephalomyelitis (EAE) in DA rats, Clin. Exp. Immunol., 111: 205-210, 1998.
99. K.J. Kennedy, W.S. Smith, S.D. Miller, and W.J. Karpus, Induction of antigen-specific tolerance for the treatment of ongoing, relapsing autoimmune encephalomyelitis - A comparison between oral and peripheral tolerance, J. Immunol., 159: 1036-1044, 1997.
100. H.L. Weiner, G.A. Mackin, M. Matsui, E.J. Orav, S.J. Khoury, D.M. Dawson, and D.A. Hafler, Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis, Science, 259: 1321-1324, 1993.
101. H.J. Burstein, C.M. Shea, and A.K. Abbas, Aqueous antigens induce in vivo tolerance selectively in IL-2- and IFN-gamma-producing (Th1) cells, J. Immunol., 148: 3687-3691, 1992.
102. J.M. Critchfield, M.K. Racke, J.C. Zuniga-Pflucker, B. Cannella, C.S. Raine, J. Goverman, and M.J. Lenardo, T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis, Science, 263: 1139-1143, 1994.
103. M.K. Racke, J.M. Critchfield, L. Quigley, B. Cannella, C.S. Raine, H.F. McFarland, and M.J. Lenardo, Intravenous antigen administration as a therapy for autoimmune demyelinating disease, Ann. Neurol., 39: 46-56, 1996.
104. E.R. Kearney, K.A. Pape, D.Y. Loh, and M.K. Jenkins, Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo, Immunity, 1: 327-339, 1994.
105. A. Gaur, B. Wiers, A. Liu, J. Rothbard, and C.G. Fathman, Amelioration of autoimmune encephalomyelitis by myelin basic protein synthetic peptide-induced anergy, Science, 258: 1491-1494, 1992.
106. S. Marusic and S. Tonegawa, Tolerance induction and autoimmune encephalomyelitis amelioration after administration of myelin basic protein-derived peptide, J. Exp. Med., 186: 507-515, 1997.
107. C.P. Genain, K. Abel, N. Belmar, F. Villinger, D.P. Rosenberg, C. Linington, C.S. Raine, and S.L. Hauser, Late complications of immune deviation therapy in a non-human primate, Science, 274: 2054-2057, 1996.
108. C.E. Smith, T.N. Eagar, J.L. Strominger, and S.D. Miller, Differential induction of IgE-mediated anaphylaxis after soluble vs. cell-bound tolerogenic peptide therapy of autoimmune encephalomyelitis, Proc. Natl. Acad. Sci. U. S. A., 102: 9595-9600, 2005.
109. R. Pedotti, D. Mitchell, J. Wedemeyer, M. Karpuj, D. Chabas, E.M. Hattab, M. Tsai, S.J. Galli, and L. Steinman, An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide, Nat. Immunol., 2: 216-222, 2001.
110. S.D. Miller, B.L. McRae, C.L. Vanderlugt, K.M. Nikcevich, J.G. Pope, L. Pope, and W. J. Karpus, Evolution of the T cell repertoire during the course of experimental autoimmune encephalomyelitis, Immunol. Rev., 144: 225-244, 1995.
111. M.K. Kennedy, L.J. Tan, M.C. Dal Canto, and S.D. Miller, Regulation of the effector stages of experimental autoimmune encephalomyelitis via neuroantigen-specific tolerance induction, J. Immunol., 145: 117-126, 1990.
112. C.L. Vanderlugt, T.N. Eagar, K.L. Neville, K.M. Nikcevich, J.A. Bluestone, and S.D. Miller, Pathologic role and temporal appearance of newly emerging autoepitopes in relapsing experimental autoimmune encephalomyelitis, J. Immunol., 164: 670-678, 2000.
113. M.K. Kennedy, L.J. Tan, M.C. Dal Canto, V.K. Tuohy, Z.J. Lu, J.L. Trotter, and S.D. Miller, Inhibition of murine relapsing experimental autoimmune encephalomyelitis by immune tolerance to proteolipid protein and its encephalitogenic peptides, J. Immunol., 144: 909-915, 1990.
114. L.-J. Tan, M.K. Kennedy, M.C. Dal Canto, and S.D. Miller, Successful treatment of paralytic relapses in adoptive experimental autoimmune encephalomyelitis via neuroantigen-specific tolerance, J. Immunol., 147: 1797-1802, 1991.
115. A.A. Vandenbark, M. Vainiene, K. Ariail, S.D. Miller, and H. Offner, Prevention and treatment of relapsing autoimmune encephalomyelitis with myelin peptide-coupled splenocytes, J. Neurosci. Res., 45: 430-438, 1996.
116. X.-M. Su, and S. Sriram, Treatment of chronic relapsing experimental allergic encephalomyelitis with the intravenous administration of splenocytes coupled to encephalitogenic peptide 91-103 of myelin basic protein, J. Neuroimmunol., 34: 181-190, 1991.
117. H. Braley-Mullen, J.G. Tompson, G.C. Sharp, and M. Kyriakos, Suppression of experimental autoimmune thyroiditis in guinea pigs by pretreatment with thyroglobulin-coupled spleen cells, Cell. Immunol., 51: 408-413, 1980.
118. H.S. Dua, D.S. Gregerson, and L.A. Donoso, Inhibition of experimental autoimmune uveitis by retinal photoreceptor antigens coupled to spleen cells, Cell. Immunol., 139: 292-305, 1992.
119. S.K. Gregorian, L. Clark, E. Heber-Katz, E.P. Amento, and A. Rostami, Induction of peripheral tolerance with peptide-specific anergy in experimental autoimmune neuritis, Cell. Immunol., 150: 298-310, 1993.
120. L.J. Tan, M.K. Kennedy, and S.D. Miller, Regulation of the effector stages of experimental autoimmune encephalomyelitis via neuroantigen-specific tolerance induction. II. Fine specificity of effector T cell inhibition, J. Immunol., 148: 2748-2755, 1992.
121. T.N. Eagar, N.J. Karandikar, J. Bluestone, and S.D. Miller, The role of CTLA-4 in induction and maintenance of peripheral T cell tolerance, Eur. J. Immunol., 32: 972-981, 2002.
122. L. Pope, P.Y. Paterson, and S.D. Miller, Antigen-specific inhibition of the adoptive transfer of experimental autoimmune encephalomyelitis in Lewis rats, J. Neuroimmunol., 37: 177-190, 1992.